{
  "docId": "019de076-39d2-7099-ad19-065ffc77ed59",
  "docSlug": "e110bee9f1b318f547399ddf66ee5ee3",
  "documentTitle": "Exscientia | Results Presentation Deck | 24 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 24,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "overcrowded",
  "nDataPoints": 14,
  "notes": "The table uses a heatmap-style color coding (red for high risk, green for low risk) to visualize safety metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-39d2-7099-ad19-065ffc77ed59/19",
  "deckHref": "/decks/019de076-39d2-7099-ad19-065ffc77ed59",
  "deckJsonHref": "/decks/019de076-39d2-7099-ad19-065ffc77ed59.json",
  "deckAnchorHref": "/decks/019de076-39d2-7099-ad19-065ffc77ed59#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.22,
        "w": 0.42,
        "x": 0.51,
        "y": 0.25
      },
      "kind": "list",
      "text": "‘565 has a low risk of potential DDI/ hyperbilirubinaemia at predicted human efficacious doses. Potential for safer dose escalation for ‘565 to reach the level of target engagement necessary to achieve clinical efficacy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c2c9531-8535-4c23-9e2a-4f5f724629db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.42,
        "x": 0.07,
        "y": 0.25
      },
      "kind": "list",
      "text": "We predict that selectivity over UGT1A1 could be an issue for some clinical stage MALT1 inhibitors. Inhibition of UGT1A1 mediates bilirubin glucuronidation, potentially leading to hyperbilirubinaemia.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c81b1da-e0a1-4ed7-a405-cda9b659160c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Payne et al. ESMO, 2023. 1) Hertzberg et al. Hematol Oncol, 2023; Cmax,u: Predicted maximum free plasma; Imax,u,inlet: free liver inlet concentration",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "814dff8d-d4bb-40a3-b714-2a2adf096dfc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.94,
        "x": 0.03,
        "y": 0.64
      },
      "kind": "table",
      "text": "Compound, Best-estimate Scenario, Cmax,u, IC50, IC50/Imax,u,inlet, Rfree, Rin,free, Fi, Prediction. Pharma Phase 1b: 127h, 0.28, 0.76, 2.4, 1.37, 1.42, 0.27, Risk. '565: 39h, 0.30, >10, 34, 1.02, 1.03, 0.02, Low Risk.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9739f58-5b06-4ace-988c-46da2d5b6831",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Potential safety benefit compared with clinical MALT1i in development",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cc546307-9a96-487e-bfac-d3f24b7c0977",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "‘565 has a low predicted risk of hyperbilirubinaemia",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e4315ea-8486-43f1-a64c-816bf2c1b565",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "8bf45e9c-3703-4b19-b693-2e5e7c0e2b41",
      "evidence": "Potential safety benefit compared with clinical MALT1i in development",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "e1afbaf7-6252-4798-8384-f0ad48b2170c",
      "evidence": "Table compares two compounds across multiple safety metrics to highlight a competitive advantage.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}